Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

NCT04365101 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronavirus
Coronavirus Infection
Severe Acute Respiratory Syndrome Coronavirus 2
Pneumonia
Pneumonia, Viral
Lung Diseases
Respiratory Tract Disease
Respiratory Tract Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Disease
Immunologic Disease
ARDS
Immunologic Factors
Physiological Effects of Drugs
Antiviral Agents
Anti-infective Agents
Analgesics
Antimetabolites, Antineoplastic

Interventions

BIOLOGICAL: CYNK-001

Sponsor

Celularity Incorporated

Collaborators

[object Object]
[object Object]
[object Object]